Cardiovascular prevention


by subject classification

ACAT inhibition

all type of patients - pdf

Anticoagulant - acenocoumarol - betrixaban - phenindione

all type of patients - pdf

secondary prevention - pdf

primary prevention - pdf

Antioxydants - beta carotene - vitamin c - vitamin e

secondary prevention - pdf

diabetic patients - pdf

all type of patients - pdf

patients with renal disease - pdf

primary prevention - pdf

Antiplatelets drug - A EFFACER - aspirin - atopaxar - cangrelor - clopidogrel - dipyridamol - elinogrel - prasugrel - sulfinpyrazone - ticagrelor - ticlopidine - triflusal - vorapaxar

secondary prevention in patients with intermittent claudication - pdf

secondary prevention in patients with CAD - pdf

primary prevention - pdf

patients without established disease - pdf

secondary prevention - pdf

diabetic patients - pdf

all type of patients - pdf

Antithrombotics - abciximab - apixaban - bivalirudin - coumadin - dabigatran - deltaparin - dicoumarol - edoxaban - eptifibatide - fondaparinux - fraxiparin - heparin - hirudin - idraparinux - LMWH - reviparin - rivaroxaban - tirofiban - UFH - wafarin - warfarin - ximelagatran

diabetic patients - pdf

primary prevention - pdf

patienst at high risk - pdf

secondary prevention - pdf

all type of patients - pdf

CEPT inhibition - anacetrapib

all type of patients - pdf

Cholesterol lowering intervention - atorvastatin - bezafibrate - cerivastatin - cholestyramine - clofibrate - colestipol - diet - etofibrate - ezetimibe - fenofibrate - fluvastatin - gemfibrozil - lovastatin - niacin - policosanol - pravastatin - probucol - rosuvastatin - simvastatin

elderly - pdf

high risk patients with or without LDL cholesterol elevation - pdf

women - pdf

patients with prior MI or with CHD - pdf

primary prevention - pdf

patients with renal insufficiency (on hemodialysis or transplant) - pdf

patients with other atherosclerotic localisation - pdf

patient with related disease - pdf

all chronical situations - pdf

post stroke (or TIA) - pdf

patients with LDL elevation and without CHD - pdf

diabetic patients - pdf

Diet

all type of patients - pdf

Dietary salt reduction

all type of patients - pdf

hypertensive patients - pdf

normotensive subjects - pdf

Direct factor Xa inhibitors

secondary prevention - pdf

Direct oral anticoagulant (DAO)

secondary prevention - pdf

HDL increasing drugs - torcetrapib

all type of patients - pdf

Hormonal replacement therapy

all type of patients - pdf

primary prevention - pdf

secondary prevention - pdf

Lifestyle intervention

all type of patients - pdf

primary prevention - pdf

secondary prevention - pdf

Niacin

all type of patients - pdf

Omega-3 fatty acids - fish oil

all type of patients - pdf

patients at high risk - pdf

pateints at low risk - pdf

patients with an implantable cardioverter defibrillator - pdf

On top statins

all type of patients - pdf

PCSK9 Inhibitors - alirocumab - bococizumab - evolocumab

all type of patients - pdf

Plasma homocysteine lowering intervention

secondary prevention - pdf

primary prevention - pdf

all type of patients - pdf

patients with chronic kidney disease - pdf

Polypill

all type of patients - pdf

Statins

primary prevention - pdf

secondary prevention - pdf

diabetic patients - pdf

hypertensive patients - pdf

Weight-loss drugs - orlistat

all type of patients - pdf

overweight or obese patients - pdf

diabetic patients - pdf